Immunocore (NASDAQ:IMCR) Raised to Buy at Wall Street Zen

Immunocore (NASDAQ:IMCR) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

Several other equities analysts have also recently commented on IMCR. Jefferies Financial Group cut Immunocore from a “buy” rating to a “hold” rating and reduced their target price for the stock from $48.00 to $33.00 in a research report on Monday, March 16th. HC Wainwright reiterated a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Monday, April 20th. Zacks Research cut shares of Immunocore from a “hold” rating to a “strong sell” rating in a research report on Monday, April 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a research note on Tuesday, April 21st. Finally, Needham & Company LLC lifted their target price on shares of Immunocore from $71.00 to $75.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $57.75.

Immunocore Stock Performance

NASDAQ IMCR opened at $29.58 on Friday. Immunocore has a 1 year low of $27.44 and a 1 year high of $40.71. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.18 and a quick ratio of 4.15. The stock has a market capitalization of $1.50 billion, a PE ratio of -53.78 and a beta of 0.74. The company’s 50 day simple moving average is $30.87 and its two-hundred day simple moving average is $33.32.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.51. The firm had revenue of $106.68 million during the quarter, compared to analyst estimates of $145.20 million. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. The business’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 EPS. Analysts predict that Immunocore will post -0.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Bahija Jallal sold 11,474 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total value of $371,183.90. Following the completion of the sale, the chief executive officer owned 12,343 shares in the company, valued at $399,296.05. The trade was a 48.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider David M. Berman sold 5,965 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $192,967.75. Following the transaction, the insider owned 5,859 shares in the company, valued at $189,538.65. The trade was a 50.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 19,137 shares of company stock worth $619,082 in the last quarter. 10.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Immunocore

Large investors have recently added to or reduced their stakes in the business. Harbour Investments Inc. boosted its position in Immunocore by 60.2% during the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after buying an additional 388 shares during the period. DNB Asset Management AS increased its holdings in shares of Immunocore by 6.4% in the third quarter. DNB Asset Management AS now owns 8,116 shares of the company’s stock worth $295,000 after buying an additional 488 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Immunocore by 37.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock valued at $74,000 after acquiring an additional 572 shares during the last quarter. R Squared Ltd boosted its holdings in Immunocore by 7.4% during the 4th quarter. R Squared Ltd now owns 8,849 shares of the company’s stock valued at $307,000 after acquiring an additional 606 shares during the period. Finally, Leonteq Securities AG purchased a new stake in Immunocore during the 4th quarter valued at about $30,000. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Key Stories Impacting Immunocore

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: HC Wainwright raised multiple 2027–2028 earnings estimates for Immunocore and maintained a Buy rating with a $100 price target, signaling confidence in the company’s longer-term growth outlook.
• Positive Sentiment: Zacks Research upgraded Immunocore from strong sell to strong-buy, adding to the bullish tone around the stock.
• Neutral Sentiment: Recent commentary also highlighted Immunocore’s valuation after strong Q1 2026 results and new KIMMTRAK survival data, which may be reinforcing investor interest. A Look At Immunocore (IMCR) Valuation After Strong Q1 2026 Results And New KIMMTRAK Survival Data
• Negative Sentiment: Not all forecast changes were positive: HC Wainwright trimmed its FY2029 and FY2030 EPS estimates slightly, which tempers the overall optimism.

Immunocore Company Profile

Immunocore plc is a clinical?stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T?cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T?cell receptors against cancer) platform utilizes engineered, soluble T?cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease?associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma?associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.